GlassScriptPhysician profile
Jennifer E Canfield
NPI 1467481119
$9,057.22
in general payments reported to CMS, 2019-2025
55 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,760 · 2022: $2,024 · 2023: $1,750 · 2024: $1,170 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,438.47 | 2021-2025 | |
| Pfizer INC. | $1,018.41 | 2021-2025 | |
| Novo Nordisk INC | $880.03 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $470.08 | 2021-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $414.14 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $383.01 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $356.57 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $330.17 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $317.93 | 2021-2025 | Nexletol |
| Amgen INC. | $310.00 | 2021-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $293.02 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.75 | 2021-2023 | Tradjenta, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $230.75 | 2021-2024 | Trintellix |
| Corium, LLC | $197.75 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $176.44 | 2021-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Canfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.